Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS) has been given an average rating of “Moderate Buy” by the ten ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $326.25.

Several research firms have recently issued reports on KRYS. Weiss Ratings lowered Krystal Biotech from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday. Citigroup increased their price target on Krystal Biotech from $336.00 to $371.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. TD Cowen restated a “buy” rating on shares of Krystal Biotech in a research report on Friday, January 9th. Guggenheim lifted their price objective on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Finally, The Goldman Sachs Group boosted their price objective on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research report on Friday, January 30th.

Krystal Biotech Trading Down 1.4%

Shares of NASDAQ KRYS opened at $251.40 on Friday. Krystal Biotech has a 12-month low of $122.80 and a 12-month high of $298.30. The firm’s 50-day moving average price is $268.13 and its 200-day moving average price is $228.50. The stock has a market capitalization of $7.35 billion, a price-to-earnings ratio of 36.70 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.The company had revenue of $107.11 million during the quarter, compared to analyst estimates of $105.30 million. On average, equities analysts predict that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Activity

In related news, CAO Kathryn Romano sold 12,500 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $272.14, for a total value of $3,401,750.00. Following the sale, the chief accounting officer directly owned 19,318 shares of the company’s stock, valued at $5,257,200.52. This represents a 39.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Daniel Janney sold 37,895 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $266.88, for a total transaction of $10,113,417.60. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 129,164 shares of company stock valued at $34,538,578 in the last quarter. 13.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds and other institutional investors have recently modified their holdings of KRYS. Royal Bank of Canada lifted its stake in shares of Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after acquiring an additional 964 shares during the last quarter. AQR Capital Management LLC increased its stake in Krystal Biotech by 29.9% in the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after purchasing an additional 2,792 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Krystal Biotech by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock worth $2,870,000 after purchasing an additional 688 shares during the period. Empowered Funds LLC bought a new stake in shares of Krystal Biotech during the first quarter worth $218,000. Finally, Cetera Investment Advisers boosted its stake in shares of Krystal Biotech by 107.9% during the second quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock valued at $597,000 after purchasing an additional 2,255 shares during the period. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.